Editas Medicine Inc. (NASDAQ:EDIT) was up 3.3% during trading on Thursday . The stock traded as high as $19.43 and last traded at $18.95, with a volume of 143,067 shares traded. The stock had previously closed at $18.35.

Several equities research analysts recently commented on EDIT shares. Vetr upgraded shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $32.50 target price on the stock in a research report on Monday, May 9th. Zacks Investment Research downgraded shares of Editas Medicine from a “hold” rating to a “sell” rating in a research report on Wednesday, May 18th. Jefferies Group restated a “buy” rating on shares of Editas Medicine in a research report on Monday. Finally, Cowen and Company restated a “buy” rating on shares of Editas Medicine in a research report on Monday, May 16th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $33.50.

The stock’s market cap is $649.66 million. The stock has a 50-day moving average price of $23.70 and a 200 day moving average price of $29.21.

Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.54) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.54). Analysts forecast that Editas Medicine Inc. will post ($2.59) earnings per share for the current fiscal year.

Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.